Boehringer Ingelheim and Lilly present full results of Tradjenta®'s CARMELINA® cardiovascular outcome trial

Author's Avatar
Oct 04, 2018
Article's Main Image

- Tradjenta® (linagliptin) demonstrated similar long-term cardiovascular safety compared with placebo in adults with type 2 diabetes

- The overall safety profile of Tradjenta in the trial, including adults with kidney disease, was consistent with previous data and no new safety signals were observed

- The results of CARMELINA® were presented at the 54th EASD Annual Meeting today

PR Newswire